Bapineuzumab
Based on 1 Customer Validation
Bapineuzumab (AAB-001) is a humanized IgG1 monoclonal antibody that binds to the N-terminal region of amyloid beta in a helical conformation. Bapineuzumab induces microglial activation by upregulating CD11B, producing pro-inflammatory cytokines (IL-1β and TNFα), clearing plaques, and reducing insoluble and aggregated Aβ. Bapineuzumab can be used for research on Alzheimer's disease.
For research use only. We do not sell to patients.
- Purity : 99.00%
- CAS No.: 648895-38-9
- Molecular Weight:144.5 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-P99022
GantenerumabAnti-Aβ Monoclonal Antibody -
HY-P9967
AducanumabAnti-Aβ Monoclonal Antibody -
HY-P99859
DonanemabAnti-Aβ Antibody -
HY-P99317
SolanezumabAnti-Aβ Antibody -
HY-P99835
CrenezumabAnti-Aβ Antibody -
HY-P1363A
β-Amyloid (1-42), humanAmyloid β Peptide -
HY-P9999
TrontinemabAβ/TFRC Antibody -
HY-P1363B
β-Amyloid (1-42), human, HFIP-treatedβ-Amyloid (1-42) Peptide -
HY-19370
FPS-ZM1Amyloid-β Inhibitor -
HY-17406
TolcaponeCOMT Inhibitor -
HY-N0615
Notoginsenoside R1Apoptosis Inhibitor -
HY-103240
Methoxy-X04Fluorescent Dye
Biological Activity
Description
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
In Vitro
The murine version of Bapineuzumab binds Aβ plaques in human AD brain tissue without requiring formic acid antigen retrieval, with improved staining following formic acid treatment[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:RAW 264.7
-
Concentration:5 µg/mL
-
Incubation Time:24 h
-
Result:Stimulated secretion of the cytokine TNFα compared to cell only controls.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:APP23 mice (B6.Cg-Tg(Thy1-APP)3Somm/J, male, 27 months old)[2]
-
Dosage:12.4 mg/kg
-
Administration:i.p.; twice, 5 days apart
-
Result:Induced a mean of 4.5 new lesions at t1 and 5.3 new lesions at t2.
Induced a mean of 3.2 new lesions in the cortex at t1 and 2.8 at t2.
Induced a mean of 1.2 new lesions in the thalamus/striatum at t1 and 1.8 at t2.
Induced a mean of 0.2 new lesions in the hippocampus at t1 and 0.3 at t2.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Flow cytometric analysis of 1.5×106 HUVEC cells with Bapineuzumab (HY-P99185, red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa, Isotype Control (HY-P99001, blue) was used as the isotype control.
Chemical Information
-
CAS No. 648895-38-9
-
Appearance Liquid
-
Molecular Weight 144.5 kDa
-
Color Colorless to light yellow
-
SMILES
[Bapineuzumab]
-
Synonyms
AAB-001
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Fuller JP, et al. Comparing the efficacy and neuroinflammatory potential of three anti-abeta antibodies. Acta neuropathologica. 2015 Nov;130(5):699-711. [Content Brief]
[3]. Salloway S, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. The New England journal of medicine. 2014 Jan 23;370(4):322-33. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Bapineuzumab Related Classifications
HY-P99185 Related Classifications
Powered by Bioz